Sublocade - Page 1 | CARLAT PUBLISHING

Fact Sheet

Buprenorphine (Brixadi, Sublocade) Fact Sheet [G]

January 1, 2026

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Buprenorphine (Subutex, available now only as generic) is the active ingredient in Suboxone (buprenorphine/naloxone) and is responsible for the effectiveness of the combination medication in opioid use disorder.

Clinical Update

Rapid Induction of Buprenorphine in Acute Care Settings

November 1, 2025

Jaewon Lee, MD, MPH and Noah Capurso, MD, MHS

Jaewon Lee, MD, MPH. PGY-3, Psychiatry, University of Rochester Medical Center, Rochester, NY.

Noah Capurso, MD, MHS. Assistant Medical Director, Addiction Services Division, Connecticut Valley Hospital; Associate Clinical Professor of Psychiatry, Yale University; Editor-in-Chief, The Carlat Addiction Treatment Report.

Dr. Lee and Dr. Capurso have no financial relationships with companies related to this material.

New rapid induction strategies are allowing clinicians to start buprenorphine in acute care settings.

The Rise of Long-Acting Buprenorphine

September 29, 2025

Noah Capurso, MD and Geneva Valeska

There are two variations of long-acting injectable buprenorphine on the market. But what differentiates them, who might benefit, and how well do they work? Find out in today’s podcast.

Clinical Update

Brixadi: A New Long-Acting Buprenorphine Option for Opioid Use Disorder

July 1, 2025

Crystal Obiozor, MD and Noah Capurso, MD, MHS

Crystal Obiozor, MD. Assistant Professor of Psychiatry, Yale University, New Haven, CT.

Noah Capurso, MD, MHS. Assistant Medical Director, Addiction Services Division, Connecticut Valley Hospital; Associate Clinical Professor of Psychiatry, Yale University; Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Obiozor and Capurso have no financial relationships with companies related to this material.

A new long-acting injectable formulation of buprenorphine, Brixadi, is now available for the treatment of opioid use disorder. It is the second one to hit the market, after Sublocade. The two formulations share similarities, but there are some important differences to consider when choosing which medication to prescribe.

Fact Sheet

Buprenorphine Extended-Release Injection Monotherapy (Brixadi, Sublocade)

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Extended-release injectable formulations of buprenorphine allow patients to receive doses weekly, monthly, or every eight weeks for patients maintained on a low dose—which improves medication adherence.

Clinical Guidance

How to Use Sublocade and Brixadi

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Sublocade and Brixadi are long-acting forms of injectable buprenorphine given once every four or eight weeks for Sublocade and weekly or monthly for Brixadi.

Fact Sheet

Buprenorphine (Sublocade) for Children and Adolescents

September 22, 2023

Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Buprenorphine alone was previously preferred for initial (induction) phase of treatment, with buprenorphine/naloxone combination preferred for maintenance treatment (unsupervised administration).